Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Status and phase: Active, not recruiting; Phase 2; Phase 1

Conditions: Multiple Myeloma; Hematopoietic Stem Cell Transplantation

Treatments: Drug: Sirolimus; Drug: Tacrolimus; Drug: Any prophylaxis for GVHD; Drug: Ixazomib

Study type: Interventional

Funder types: Other; NETWORK

Identifiers

NCT03225417

X16082

Details and patient eligibility

About

Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many patients with hematologic malignancies but >50% of this patients will develop extensive chronic graft-versus-host disease (cGVHD), which remains the most important complication after HTC.

Classically, the most effective strategies to prevent GVHD have not improved survival; therefore, the new strategies are being sought.

This study is designed in two phases: the main objective for phase I study is the more suitable dose for ixazomib search. Phase II study is designed to evaluate the efficacy of ixazomib at the doses stablished in phase I.

Full description

The study design is based on a phase I / II trial in eight Spanish hospitals.

In the phase I, a number of 3 to 12 patients will be included to evaluate the optimal dose of ixazomib in combination with sirolimus and tacrolimus.

In the phase II, a total number of 130 patients will be randomized to receive ixazomib or the best medical recommendation added in order to evaluate the efficacy of ixazomib. This patients who will receive any prophylaxis for GVHD, except those patients who received antithymocyte globulin , cyclophosphamide or any T depletion protocol in vitro or in vivo.

Enrollment: 142 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female patients 18 years or older.

2. Patients on the day +100 +/- 20 days who have received an allogeneic transplant with myeloablative or reduced intensity conditioning peripheral blood allogeneic stem cell transplantation.

3. Patients who have received a hematopoietic bone marrow transplant hematopoietic progenitors of peripheral blood from histo / compatible donor as definition accepted by protocol.

4. Patients receiving any prophylaxis for GVHD, except for antithymocyte globulin, cyclophosphamide or any in vitro or in vivo depletion protocol.

5. Voluntary written consent must be given before performance of any study related procedure.

6. Female patients who accomplish with requisitions for not possibility of pregnancy (menopausal, effective methods of contraception), as detailed by protocol.

7. Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2.

8. Patients must meet the following clinical laboratory criteria:

   • Absolute neutrophil count 1,000/mm3 and platelet count 75,000/mm3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment.
   • Total bilirubin 1.5 the upper limit of the normal range .
   • Alanine aminotransferase and aspartate aminotransferase 3 upper limit of the normal range.
   • Calculated creatinine clearance 30 mL/min.

9. Ability to swallow and tolerate oral medication.

10. Absence of gastrointestinal symptoms that precludes oral intake and absorption.

11. Off antibiotics and amphotericin B formulations, voriconazole or other anti-fungal therapy for the treatment of active proven, probable or possible infections.

12. Ability to understand the nature of this study and give written informed consent.

Exclusion criteria

1. Female patients who are lactating or have a positive serum pregnancy test during the screening period.
2. Major surgery within 14 days before enrollment.
3. Central nervous system involvement with malignant cells.
4. Uncontrolled infection within 14 days before study enrollment.
5. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
6. Systemic treatment, within 14 days before the first dose of ixazomib, with strong Cytochrome P450, family 3, subfamily A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.
7. Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
8. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
9. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
10. Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
11. Patient has Grade 1 with pain or ≥ grade 2 with or without pain peripheral neuropathy.
12. Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.
13. Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not.
14. Active Graft versus host disease at the time of inclusion: patients are allowed to be included if acute Graft-versus-host Disease is in complete remission and are receiving systemic steroids at < 0.25 mg / kg.
15. Active hematologic malignancy at the time of inclusion.
16. Active microangiopathy at the time of inclusion (according to International Working Group criteria).
17. Gastrointestinal disease or procedure than can interfere with oral absorption , intolerance to the ixazomib or difficulty to swallow.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

142 participants in 2 patient groups

Experimental group

Experimental group

Description:

Phase I: Ixazomib + Tacrolimus + Sirolimus. Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day. Phase II: Ixazomib+ any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo. Starting Dose of Ixazomib according to phase I.

Treatment:

Drug: Ixazomib

Drug: Any prophylaxis for GVHD

Drug: Tacrolimus

Drug: Sirolimus

Control group

Other group

Description:

Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.

Treatment:

Drug: Any prophylaxis for GVHD

Drug: Tacrolimus

Drug: Sirolimus